Page last updated: 2024-10-27

gemfibrozil and Obesity

gemfibrozil has been researched along with Obesity in 17 studies

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
" We therefore conducted a double-blind, placebo-controlled, crossover study of gemfibrozil treatment on fibrinolytic function in 21 men with combined hyperlipoproteinemia."9.08Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. ( Angelin, B; Bröijersen, A; Eriksson, M; Hjemdahl, P; Wiman, B, 1996)
"This study investigated the possible synergistic role of obesity in hypertension-induced cardiac remodeling and its modulation by gemfibrozil treatment in rats."7.77Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats. ( Krishan, P; Singh, AP; Singh, M; Singh, R, 2011)
" We therefore conducted a double-blind, placebo-controlled, crossover study of gemfibrozil treatment on fibrinolytic function in 21 men with combined hyperlipoproteinemia."5.08Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. ( Angelin, B; Bröijersen, A; Eriksson, M; Hjemdahl, P; Wiman, B, 1996)
"This study investigated the possible synergistic role of obesity in hypertension-induced cardiac remodeling and its modulation by gemfibrozil treatment in rats."3.77Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats. ( Krishan, P; Singh, AP; Singh, M; Singh, R, 2011)
"Obesity is associated with cognitive impairments."1.35Obesity and hypertriglyceridemia produce cognitive impairment. ( Abdul, HM; Banks, WA; Butterfield, DA; Farr, SA; Miller, NE; Morley, JE; Xu, L; Yamada, KA, 2008)
"Gemfibrozil treatment in non-PiZ patients also resulted in a reduction of alpha 1-AT activity which could be reproduced in vitro."1.29An interaction between Gemfibrozil and alpha 1-antitrypsin. ( Eriksson, S; Janciauskiene, S, 1994)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's7 (41.18)18.2507
2000's7 (41.18)29.6817
2010's1 (5.88)24.3611
2020's2 (11.76)2.80

Authors

AuthorsStudies
Thongnak, L1
Pengrattanachot, N1
Promsan, S1
Phengpol, N1
Sutthasupha, P1
Jaikumkao, K1
Lungkaphin, A1
Kayıkçıoğlu, M1
Shahbazova, S1
İbrahimov, F1
Can, LH1
Singh, R1
Singh, AP1
Singh, M1
Krishan, P1
Després, JP2
Lemieux, I1
Pascot, A1
Alméras, N1
Dumont, M2
Nadeau, A1
Bergeron, J2
Prud'homme, D2
Angulo, P1
Törüner, F1
Akbay, E1
Cakir, N1
Sancak, B1
Elbeg, S1
Taneri, F1
Aktürk, M1
Karakoç, A1
Ayvaz, G1
Arslan, M1
Dufour, JF1
Oneta, CM1
Farr, SA1
Yamada, KA1
Butterfield, DA1
Abdul, HM1
Xu, L1
Miller, NE1
Banks, WA1
Morley, JE1
Tenkanen, L1
Mänttäri, M1
Manninen, V1
Janciauskiene, S1
Eriksson, S1
Nemeth, A1
Szakmary, K1
Kramer, J1
Dinya, E1
Pados, G1
Fust, G1
Huettinger, M1
Bröijersen, A1
Eriksson, M1
Wiman, B1
Angelin, B1
Hjemdahl, P1
Hung, YJ1
Pei, D1
Wu, DA1
Kuo, SW1
Fuh, MM1
Jeng, C1
Mauriège, P1
Nerbrand, C1
Nyberg, P1
Nordström, L1
Samsioe, G1
Ditschuneit, HH1
Flechtner-Mors, M1
Hagel, E1
Ditschuneit, H1
Fasching, P1
Ratheiser, K1
Waldhäusl, W1
Rohac, M1
Vierhapper, H1

Reviews

2 reviews available for gemfibrozil and Obesity

ArticleYear
Current best treatment for non-alcoholic fatty liver disease.
    Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:5

    Topics: Antioxidants; Chromans; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Fatty L

2003
[Alcoholic and non-alcoholic steatohepatitis].
    Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:8

    Topics: Alcoholism; Biopsy; Cholagogues and Choleretics; Diagnosis, Differential; Fatty Liver; Fatty Liver,

2004

Trials

7 trials available for gemfibrozil and Obesity

ArticleYear
Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome.
    Arteriosclerosis, thrombosis, and vascular biology, 2003, Apr-01, Volume: 23, Issue:4

    Topics: Adult; Body Constitution; C-Reactive Protein; Coronary Artery Disease; Gemfibrozil; Humans; Hyperlip

2003
Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study.
    Circulation, 1995, Oct-01, Volume: 92, Issue:7

    Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Gemf

1995
Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels.
    Arteriosclerosis, thrombosis, and vascular biology, 1996, Volume: 16, Issue:4

    Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fibrinolysis; Gemfibrozil; Humans; Hyperlipopr

1996
Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2001, Volume: 25, Issue:8

    Topics: Adipose Tissue; Area Under Curve; Blood Glucose; Cholesterol; Gemfibrozil; Glucose Tolerance Test; H

2001
Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
    Maturitas, 2002, May-20, Volume: 42, Issue:1

    Topics: Administration, Oral; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Estr

2002
Postprandial lipoprotein metabolism in obese patients with moderate hypertriglyceridaemia: effects of gemfibrozil.
    The Journal of international medical research, 1992, Volume: 20, Issue:3

    Topics: Adult; Apolipoproteins; Body Mass Index; Cholesterol; Eating; Fasting; Female; Gemfibrozil; Humans;

1992
[Fish oil as lipostatic factor].
    VASA. Supplementum, 1990, Volume: 30

    Topics: Adult; Diabetic Angiopathies; Female; Fish Oils; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Male;

1990

Other Studies

8 other studies available for gemfibrozil and Obesity

ArticleYear
Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway.
    Archives of pharmacal research, 2023, Volume: 46, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Gemfibrozil; Insulin; Insulin Resistance; Ki

2023
Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2020, Volume: 48, Issue:4

    Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cost of Illness; Di

2020
Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats.
    Free radical biology & medicine, 2011, Jan-15, Volume: 50, Issue:2

    Topics: Animals; Aorta, Abdominal; Blood Pressure; Cardiomegaly; Dietary Fats; Gemfibrozil; Glutathione; Hea

2011
Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2004, Volume: 36, Issue:4

    Topics: Adipose Tissue; Animals; Dietary Fats; Energy Metabolism; Gemfibrozil; Hypoglycemic Agents; Hypolipi

2004
Obesity and hypertriglyceridemia produce cognitive impairment.
    Endocrinology, 2008, Volume: 149, Issue:5

    Topics: Animals; Avoidance Learning; Cognition Disorders; Diet, Atherogenic; Excitatory Postsynaptic Potenti

2008
An interaction between Gemfibrozil and alpha 1-antitrypsin.
    Journal of internal medicine, 1994, Volume: 236, Issue:3

    Topics: alpha 1-Antitrypsin; Drug Interactions; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle Aged; Obe

1994
Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy.
    European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies, 1995, Volume: 33, Issue:11

    Topics: Adult; Aged; Alleles; Apolipoproteins; Apolipoproteins E; Cholesterol; Cholesterol, Dietary; Cholest

1995
Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 1999, Volume: 98, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Female; Gemfibr

1999